PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Notice of extraordinary general meeting in Phase Holographic Imaging PHI AB 14 March 2024
Phase Holographic Imaging PHI AB (publ), 556542-7811 (the “Company”) will hold an extraordinary general meeting on 14 March 2024 at 10.00 am at the Company’s premises, Skiffervägen 48 in Lund.
PostNews
BioStock: PHI “We aim to revolutionize the regenerative medicine market“
BioStock talked to PHI’s CEO, Patrik Eschricht, about the eventful past year and his vision for the company’s future within regenerative medicine.
PostNews: Press Release
PHI presents at the Redeye Regenerative Medicine & Cell Therapy 2024
PHI is delighted to participate in the Redeye Regenerative Medicine and Cell Therapy event on Wednesday, February 14, 2024.
PostNews: Press Release
PHI announces extraordinary quarter sales of about 5MSEK — marks the highest ever in Company history
PHI is excited to announce that preliminary Q3 net sales are summing up to approximately 5MSEK. These extraordinary quarterly net sales make it the highest ever in the Company’s history and mark an important financial milestone.
PostNews: Interim Report
Interim Report 2 2023/24
The autumn quarter marked a strategic shift in our sales organization, representing a significant move for PHI but affecting our Q2 sales. It allows us to sharpen our focus on what we do best: innovation and product development, particularly toward regenerative medicine applications.
PostNews: Press Release
PHI appoints Pareto Securities AB to act as a liquidity provider for the Company’s share
PHI has appointed Pareto Securities as the Company’s liquidity provider.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
Life is a mess
In our daily lives, we all know how important it is to plan ahead to avoid a future mess. Ironically, we ourselves are such a future mess.
Fighting cancer with nanoparticles
Using HoloMonitor, scientists at Northeastern University have shown that paclitaxel-resistant ovarian cancer cells stopped multiplying by cell division when treated with nanoparticles. Ovarian cancer causes more deaths than any other cancer of the female reproductive system.
No Blood, No Tumor
Scientists at Boston Children’s Hospital have used HoloMonitor to study living bone cancer cells. By studying their dynamics, they have successfully for the first time distinguished aggressive bone cancer cells that promote blood vessel formation from the harmless counterparts that do not promote blood vessel formation.
Big Data, Fewer Cells
Scientists at Holographic Imaging Cytometry Program of Excellence at Northeastern University have developed a method to compare time series data of drug treated cells with untreated cells.
